期刊文献+

银杏叶软胶囊处方工艺研究 被引量:4

Study on formulation and technology of Gingko Softgel
暂未订购
导出
摘要 目的:确定银杏叶软胶囊的最佳处方工艺。方法:通过对软胶囊囊壳和内容物处方及软胶囊压制和干燥关键工艺的优化研究,确定银杏叶软胶囊的最佳处方工艺。结果:银杏叶软胶囊的最佳处方工艺:胶囊壳处方为明胶:水:甘油=1:0.9:0.4,添加二氧化钛为0.4%,柠檬黄为0.05%、亮蓝为0.10%和诱惑红为0.15%;内容物处方为银杏叶提取物为(粒径120目)16%,蜂蜡为5%和大豆油为79%;控制软胶囊囊壳厚度0.7mm;干燥工艺采用温度20℃,相对湿度为30%~35%,干燥24h。结论:本处方工艺稳定、可靠,适于银杏叶软胶囊的工业化生产。 Objective:To confirm the best formulation and preparation technology for Gingko Softgel.Methods:Studied the softgel formulation of dry shell and filling materials,and the critical process of encapsulating and drying to confirm the best formulation and preparation technology for Gingko Softgel.Results:The best formulation and preparation technology:softgel dry shell formulation was:Gelatin:Water:Glycerine=1:0.9:0.4,besides added in Titanium Dioxide was 0.4%,Tartrazine was 0.05%,and Brilliant Blue FCF was 0.10%,Allura Red AC was 0.15%;the filling formulation was Ginkgo Leaves Extract was(mesh size was 120 meshes) 16%,Beeswax was 5% and Soybean was 79%;the shell thickness was 0.7 mm under control;for drying process,the temperature was 20℃,relative humidity was 30%-35%,and drying time was 24 hours.Conclusion:This formulation and preparation technology is stable and reliable,suitable for industrialization produce of Ginkgo Biloba Softgel.
作者 黄舒丽
出处 《中国当代医药》 2011年第32期126-127,130,共3页 China Modern Medicine
关键词 银杏叶提取物 软胶囊 处方 工艺 Gingko leaves extract Softgel Formulation Preparation technology
  • 相关文献

参考文献8

二级参考文献66

共引文献484

同被引文献42

  • 1Nadira Binte Samad,Trishna Debnath,Michael Ye,Md.Abul Hasnat,Beong Ou Lim.In vitro antioxidant and anti-inflammatory activities of Korean blueberry(Vaccinium corymbosum L.) extracts[J].Asian Pacific Journal of Tropical Biomedicine,2014,4(10):807-815. 被引量:6
  • 2中风病诊断与疗效评定标准(试行)[J].北京中医药大学学报,1996,19(1):55-56. 被引量:6390
  • 3各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33093
  • 4Golomb MR.Outcomes of perinatal arterial ischemic stroke and cerebral sinovenous thrombosis[J].Seminars in fetal&neonatal medicine,2009,14(5):318-322.
  • 5Yamada N.Atherosclerosis from the point of view of hypothesis to evidence based medicine[J].Nihon rinsho.Japanese journal of clinical medicine,2011,69(1):7-12.
  • 6Mierzecki A,Bukowska H,Koda K,et al.Homocysteine and metabolic risk factors in individuals with family history of premature ischemic stroke[J].Polskie Archiwum Medycyny Wewntrznej,2013,123(6):282-288.
  • 7Hojs Fabjan T,Penko M,Hojs R.Cystatin C,creatinine,estimated glomerular filtration,and long-term mortality in stroke patients[J].Renal failure,2014,36(1):81-86.
  • 8Tuttolomondo A,Di Raimondo D,Pecoraro R,et al.Immuneinflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke[J].Atherosclerosis 2010,213(1):311-318.
  • 9Pérez-de-Puig I,Martín A,Gorina R,et al.Induction of hemeoxygenase-1 expression after inhibition of hemeoxygenase activity promotes inflammation and worsens ischemic brain damage in mice[J].Neuroscience,2013,243:22-32.
  • 10Conforto AB,Leite Cda C,Nomura CH,et al.Is there a consistent association between coronary heart disease and ischemic stroke caused by intracranial atherosclerosis[J].Arquivos de neuro-psiquiatria,2013,71(5):320-326.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部